AbbVie Inc. Debt/Assets

Debt/Assets of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Debt/Assets for the quarter ending March 30, 2020 was 73.52% (a -1.82% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Assets increased by 12.74%
  • Annual Debt/Assets for 2019 was 74.88% (a 10.25% increase from previous year)
  • Annual Debt/Assets for 2018 was 67.92% (a 28.66% increase from previous year)
  • Annual Debt/Assets for 2017 was 52.79% (a -5.29% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of AbbVie Inc.

Most recent Debt/Assetsof ABBV including historical data for past 10 years.

Interactive Chart of Debt/Assets of AbbVie Inc.

AbbVie Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 73.52%
2019 74.88% 64.61% 65.21% 65.43% 74.88%
2018 67.92% 61.22% 60.2% 53.77% 67.92%
2017 52.79% 54.9% 55.58% 56.27% 52.79%
2016 55.74% 56.0% 56.31% 59.41% 55.74%
2015 59.7% 58.59% 57.79% 57.2% 59.7%
2014 54.44% 51.99% 50.75% 50.27% 54.44%
2013 50.42% 52.42% 52.88% 55.35% 50.42%
2012 58.03% 0.0% 0.0% 0.0% 58.03%
2011 0.25% 0.0% 0.0% 0.0% 0.25%
2010 0.0% 0.0%
2009 0.0% 0.0%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.